Sign in
CompletedNo phase

Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk

Key facts

Who runs it
Ain Shams University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
100 people enrolled
Started
1 Jul 2023
Ended
1 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Thrombolytic therapy for the study group in the form of streptokinase or recombinant tissue plasminogen activator
  • Unfractionated Heparin IV
Record updated
29 January 2026

Who can take part

Age
25 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Patients with intermediate high risk pulmonary embolism diagnosed according to clinical probability using revised Geneva Score and diagnosis confirmed by echocardiography and Troponin I or T level and CT pulmonary angiography

Who cannot take part

  • Ischaemic stroke in previous 6 months
  • Major trauma, surgery, or head injury in previous 3 weeks
  • Transient ischaemic attack in previous 6 months
  • o High risk PE; Intermediate low risk PE; low risk PE; Patients with left ventricular systolic dysfunction (ischemic or non-ischemic etiology); Patients with chronic lung diseases (obstructive or restrictive); Patients with contraindications to thrombolysis:
  • History of haemorrhagic stroke or stroke of unknown origin
  • Active bleeding
  • Severe hypertension (systolic BP >180 mmHg)
  • Advanced liver disease
  • Active Peptic ulcer
  • Patients who develop hypotension or bradycardia or allergic reaction requiring discontinuation of Streptokinase infusion
  • Patients with HAS-BLED score greater than or equals 3 (high bleeding risk for thrombolysis)
  • Bleeding diathesis (known inherited bleeding disorder, for example, haemophilia, platelet count <50,000/uL)
  • Central nervous system neoplasm
  • Oral anticoagulation
  • Pregnancy or first post-partum week
  • Non-compressible puncture sites
  • Traumatic resuscitation
  • Infective endocarditis

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of investigators was to study the effect and safety of Thrombolysis in Intermediate high risk pulmonary embolism patients with low bleeding risk as regards Mortality and bleeding events.

The 2 groups in the trial

  • Control groupExisting treatment, for comparison

    This arm will receive standard anticoagulation in the form of intravenous unfractionated heparin

    Treatment: Unfractionated Heparin IV

  • Study groupExisting treatment, for comparison

    This arm will receive thrombolytic therapy in the form of either streptokinase or recombinant tissue plasminogen activator

    Treatment: Thrombolytic therapy for the study group in the form of streptokinase or recombinant tissue plasminogen activator

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
29 January 2026